title: 67Ga whole-body scintigraphy in the evaluation of head and neck squamous cell carcinoma.
abstract: The diagnostic accuracy of 67Ga-citrate whole-body scintigraphy for the evaluation of primary tumours, local recurrences, cervical node metastases and distant metastases was investigated in patients with head and neck squamous cell carcinoma (SCC). Altogether, 102 67Ga-citrate whole-body scans were performed on 83 patients with head and neck SCC using a dual-headed gamma camera. The results were compared with those of computed tomography (CT) and final diagnosis. 67Ga scintigraphy correctly diagnosed 28 of 29 primary lesions, a sensitivity of 97% (CT = 97%). For tumour recurrence, 67Ga scintigraphy correctly diagnosed 13 of 15 recurrences and 53 of 58 instances of no recurrence, giving a sensitivity of 87% and a specificity of 91% (CT = 80 and 62%, respectively). Scintigraphy correctly diagnosed 23 of 31 metastatic sides of the neck and all 173 negative sides of the neck, giving a sensitivity of 74% and a specificity of 100% (CT = 90 and 84%, respectively). Finally, scintigraphy correctly diagnosed all 12 distant metastases as well as 86 of 90 cases of no metastasis, resulting in a sensitivity of 100% and a specificity of 96%. Furthermore, in five patients, distant metastases were initially detected on 67Ga scintigraphy. In conclusion, 67Ga whole-body scintigraphy with a dual-headed camera resulted in a high sensitivity and specificity for the detection of primary lesions, recurrences and distant metastases of head and neck SCC. Although the sensitivity for detecting neck node metastases was relatively low, the specificity was high. Thus, 67Ga scintigraphy is an effective technique for the evaluation of head and neck SCC, especially tumour recurrence and distant metastases.
authors.affiliation: Department of Radiology, Faculty of Medicine, Tokyo Medical and Dental University, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Murata
authors.forename: R
authors.initials: R
authors.lastname: Ishida
authors.forename: I
authors.initials: I
authors.lastname: Umehara
authors.forename: N
authors.initials: N
authors.lastname: Ishikawa
authors.forename: A
authors.initials: A
authors.lastname: Komatsuzaki
authors.forename: T
authors.initials: T
authors.lastname: Kurabayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Ishii
authors.forename: I
authors.initials: I
authors.lastname: Ogura
authors.forename: J
authors.initials: J
authors.lastname: Ishii
authors.forename: N
authors.initials: N
authors.lastname: Okada
authors.forename: H
authors.initials: H
authors.lastname: Shibuya
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging* / Q000473:pathology; D002951:Citrates; D015331:Cohort Studies; D005260:Female; D005708:Gallium; D005710:Gallium Radioisotopes; D015902:Gamma Cameras; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D019275:Radiopharmaceuticals; D012008:Recurrence; D015203:Reproducibility of Results; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed
chemical_list: D002951:Citrates; D005710:Gallium Radioisotopes; D019275:Radiopharmaceuticals; D005708:Gallium; C103850:gallium citrate